Donidalorsen Sodium is an antisense oligonucleotide commercialized by Ionis Pharmaceuticals, with a leading Phase III program in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency). According to Globaldata, it is involved in 6 clinical trials, of which 4 were completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Donidalorsen Sodium’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Donidalorsen Sodium is expected to reach an annual total of $356 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Donidalorsen Sodium Overview
Donidalorsen sodium (IONIS-PKKLRx) is under development for the treatment of Coronavirus disease 2019 (COVID-19), hereditary angioedema(HAE). It is administered through subcutaneous route. The therapeutic candidate acts by targeting plasma kallikrein. It is developed based on ligand-conjugated anti-sense(LICA) technology, designed to enhance the delivery of the drugs to particular tissues.
Ionis Pharmaceuticals Overview
Ionis Pharmaceuticals (Ionis), formerly Isis Pharmaceuticals, focuses on the discovery and development of RNA-targeted drugs. The company develops medicines to treat various diseases including cancer, pulmonary, cardiovascular diseases, neurological and infectious diseases. Its major products include Spinraza for spinal muscular atrophy, Tegsedi for neuropathy and Waylivra for familial chylomicronemia syndrome. Ionis also has a pipeline of products in different phases of clinical trials. It develops products based on its proprietary antisense technology. The company partnered with other pharmaceutical companies to develop a range of products in different therapeutic areas. The company sells its products in North America and Europe. Ionis is headquartered in Carlsbad, California, the US.
The company reported revenues of (US Dollars) US$587.4 million for the fiscal year ended December 2022 (FY2022), a decrease of 27.5% over FY2021. The operating loss of the company was US$410.2 million in FY2022, compared to an operating loss of US$38.8 million in FY2021. The net loss of the company was US$269.7 million in FY2022, compared to a net loss of US$28.6 million in FY2021. The company reported revenues of US$144.2 million for the third quarter ended September 2023, a decrease of 23.5% over the previous quarter.
For a complete picture of Donidalorsen Sodium’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.